Use of ejection fraction (or lack thereof), morbidity/mortality and heart failure drug trials: A review

International Journal of Cardiology

Volumn 84, Issue 2-3, 2002, Pages 119-132

  Fogel, Mark A ^a  

^a Division of Cardiology   (United States)

Author keywords

Contractility; Drugs; Ejection fraction; Heart failure

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLOSEQUINAN; HYDRALAZINE; IBOPAMINE; ISOSORBIDE DINITRATE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; MIBEFRADIL; MILRINONE; MOXONIDINE; PIPERANOMETOZINE; PRAZOSIN; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VALSARTAN; XAMOTEROL;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFECT; HEART AFTERLOAD; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART PERFORMANCE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART STROKE VOLUME; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RADIOISOTOPE VENTRICULOGRAPHY; REVIEW; SURVIVAL;

HEART FAILURE, CONGESTIVE; HUMANS; MORBIDITY; PREDICTIVE VALUE OF TESTS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0036074147     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00134-1     Document Type: Review

References (94)

1. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
2. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure
3. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure
4. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure
5. Statistical significance of the Veterans Administration vasodilator heart failure trial results
6. Hemodynamic correlates of left versus right ventricular radionuclide volumetric responses to vasodilator therapy in congestive heart failure secondary to ischemic or dilated cardiomyopathy
7. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
8. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
9. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial
10. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS)
11. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
12. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
13. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure
14. Controlled trial of captopril in chronic heart failure: A rest and exercise hemodynamic study
15. Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure
16. Low-dose enalapril in severe chronic heart failure
17. Factors influencing exercise performance in patients with left ventricular dysfunction
18. Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction
19. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular function after myocardial infarction
20. What is the ideal study design for evaluation and treatment for heart failure? Insights from trials assessing the effects of ACE inhibitors on exercise capacity
21. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study (ELITE)
22. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study, ELITE II
23. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: Results of the ELITE ventricular function substudy
24. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
25. Effect of chronic beta-adrenergic blockade in congestive cardiomyopathy
26. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy
27. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy
28. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy
29. A randomized trial of low-dose beta blockade therapy for idiopathic dilated cardiomyopathy
30. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial
31. Beneficial effects of metoprolol in heart failure associated with coronary artery disease
32. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy
33. Carvedilol improves left ventricular function and symptoms in chronic heart failure
34. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial
35. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure (MOCHA)
36. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
37. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease
38. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
39. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group
40. (beta)-Adrenergic receptor blockade in chronic heart failure
41. Effect of carvedilol on survival in severe chronic heart failure
42. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
43. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
44. Left ventricular anti-remodeling during β-blockade with Metoprolol in the treatment of chronic heart failure
45. Antiremodeling effects of the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure
46. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis
47. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy
48. Design of the Beta-Blocker Evaluation Survival Trial (BEST)
49. A trial of the beta blocker bucindolol in patients with advanced chronic heart failure
50. Hemodynamic, myocardial functional and neurohormonal responses to β-blockade in black versus non-black patients in BEST
51. Effect of β-blockade on mortality in African-Americans: The β-Blocker Evaluation of Survival Trial
52. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
53. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study
54. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study
55. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials
56. Clinical effects of b-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials
57. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial
58. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors
59. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure
60. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure
61. The effect of digoxin on mortality and morbidity in patients with heart failure
62. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor
63. ACE inhibitor co-therapy in patients with heart failure: Rationale for the Randomized Aldactone Evaluation Study (RALES)
64. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
65. The treatment of heart failure
66. Effect of amlodipine on morbidity and mortality in severe chronic heart failure
67. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction
68. Effect of mibefradil, a t-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure. The MACH-1 Study
69. Effect of oral milrinone on mortality in severe chronic heart failure
70. Multicenter trial of oral enoxamine in patients with moderate to moderately severe congestive heart failure: Lack of benefit when compared with placebo
71. Multicenter trial of imazodan in patients with chronic congestive heart failure
72. Indolidan (a new phosphodiesterase inhibitor) in chronic heart failure
73. Classification of positive inotropic agents
74. Evaluation of a new bipyridine inotropic agent - Milirinone - In patients with severe congestive heart failure
75. Effects of vesnarinone on morbidity and mortality in patients with heart failure
76. Meeting highlights in the section: Cardiovascular news
77. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the Flosequinan - ACE Inhibitor Trial (FACET)
78. Effect of flosequinan on survival in chronic heart failure: Preliminary results of the PROFILE Study
79. Selective and non-selective dopamine receptor agonists: An innovative approach to cardiovascular disease treatment
80. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure
81. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure
82. Effects of a cardioselective b1 partial agonist (Corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction
83. Contrasting effects of single doses of pindolol and xamoterol on left ventricular diastolic function
84. Xamoterol, a b1-adrenoreceptor partial agonist: Review of the clinical efficacy in heart failure
85. The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors
86. Xamoterol in severe heart failure
87. Anti-arrhythmic properties of moxonidine - Implications for the MOXCON study
88. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
89. Multicentre, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure: Results of the REACH Trial
90. Importance of imaging method over imaging modality in non-invasive determination of left ventricular volumes and ejection fraction: Assessment by two- and three-dimensional echocardiography and magnetic resonance imaging
91. The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure